NZYM B Novozymes A/S Class B

Resolutions from the Annual General Meeting 2025

Resolutions from the Annual General Meeting 2025

Today, the Annual General Meeting of Novonesis (Novozymes A/S) was conducted.

 The following resolutions were made:

  • Approval of the audited Annual Report for 2024
  • Approval of distribution of profit with payment of an ordinary dividend of DKK 4.20 (corresponding to approximately EUR 0.56) per A and B share. In addition to this year-end dividend, an interim dividend of DKK 2.00 (EUR ~0.27) was disbursed on September 3, 2024.
  • Approval of the Remuneration Report for 2024 (advisory vote)
  • Approval of the remuneration of members of the Board of Directors for 2025
  • Re-election of Cornelis (Cees) de Jong as Chair of the Board of Directors
  • Re-election of Heine Dalsgaard as a member of the Board of Directors and election as new Vice Chair
  • Re-election of Lise Kaae, Kasim Kutay, Kevin Lane, Morten Otto Alexander Sommer, and Kim Stratton as members of the Board of Directors
  • Election of Monila Kothari as a new member of the Board of Directors
  • Re-election of EY Godkendt Revisionspartnerselskab as the company’s auditors in respect of statutory financial and sustainability reporting
  • Approval to renew the authorizations to the Board of Directors to implement capital increases
  • Approval to renew the authorization to the Board of Directors to acquire treasury shares
  • Approval of the authorization to the Board of Directors to distribute extraordinary dividends



Composition of the Board of Directors and its committees

After the Annual General Meeting, the Board of Directors held a board meeting to appoint members of its committees.

The Board of Directors, including its committees, is now composed as follows:

  • Cees (Cornelis) de Jong (Chair of the Board, chair of the Nomination and Remuneration Committee and member of the Audit Committee)
  • Heine Dalsgaard (Vice Chair of the Board and member of the Audit Committee)
  • Robert Nøddeskov Jensen (employee representative)
  • Lise Kaae (chair of the Audit Committee)
  • Monila Kothari (member of the Innovation Committee)
  • Kasim Kutay (member of the Nomination and Remuneration Committee)
  • Lars Bo Køppler (employee representative)
  • Kevin Lane (member of the Innovation Committee)
  • Preben Nielsen (employee representative and member of the Innovation Committee)
  • Frederikke Rose Spenner (employee representative)
  • Morten Otto Alexander Sommer (chair of the Innovation Committee)
  • Kim Stratton (member of the Nomination and Remuneration Committee)

For further information on the members of the Board of Directors, please go to

Attachment



EN
03/04/2025

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Novozymes A/S Class B

 PRESS RELEASE

Trading by management and close relations of management

Trading by management and close relations of management In accordance with article 19 in Regulation (EU) No 596/2014 of 16 April 2014 on market abuse (the “Market Abuse Regulation”) and commission delegated regulation (EU) 1052/2016of 8 March 2016, Novonesis reports the following transactions under ISIN DK0060336014, Novonesis (Novozymes) B shares under the symbol NSIS B. Please read the full announcement in PDF. Attachment

 PRESS RELEASE

Trading by management and close relations of management

Trading by management and close relations of management In accordance with article 19 in Regulation (EU) No 596/2014 of 16 April 2014 on market abuse (the “Market Abuse Regulation”) and commission delegated regulation (EU) 1052/2016of 8 March 2016, Novonesis reports the following transactions under ISIN DK0060336014, Novonesis (Novozymes) B shares under the symbol NSIS B. Please read the full annuncement in PDF. Attachment

 PRESS RELEASE

Invitation to the 2026 Annual General Meeting

Invitation to the 2026 Annual General Meeting The Annual General Meeting of Novonesis (Novozymes A/S) will be held on Monday March 23, 2026 at 4:00 pm CET at Gammel Venlighedsvej 14, DK-2970 Hoersholm, Denmark. There will also be access to the meeting from the entrance at Boege Alle 10-12, DK-2970 Hoersholm, Denmark. For further information, please refer to the enclosed invitation to convene the Annual General Meeting, including the agenda and complete proposals. BOARD OF DIRECTORSThe Board of Directors proposes the re-election of Cornelis (Cees) de Jong as Chair of the Board and Heine Da...

 PRESS RELEASE

Trading by management and close relations of management

Trading by management and close relations of management In accordance with article 19 in Regulation (EU) No 596/2014 of 16 April 2014 on market abuse (the “Market Abuse Regulation”) and commission delegated regulation (EU) 1052/2016 of 8 March 2016, Novonesis reports the following transactions under ISIN DK0060336014, Novonesis (Novozymes) B shares under the symbol NSIS B. The Executive Leadership Team members eligible for the Novozymes A/S 2023-2025 incentive program has on February 25, 2026, received the allocated shares. An overview of the number and value of shares allotted is provided...

 PRESS RELEASE

Novonesis delivered strong organic sales growth of 7% in 2025

Novonesis delivered strong organic sales growth of 7% in 2025 COPENHAGEN, Denmark – February 26, 2026. Novonesis delivered strong organic sales growth of 7% and an adjusted EBITDA margin of 37.1% in 2025. The company expects a good start to 2026 and a good year overall.  Ester Baiget, President & CEO:  “In 2025, we continued to deliver strong organic sales growth. We achieved 7% growth, an adjusted EBITDA margin of 37.1% and a strong cash flow – despite currency headwinds. Growth was broad-based across sales areas and markets, with particularly strong performance in Emerging Markets. As a...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch